Page 163 - Read Online

Page 4 of 5 Singh-Ranger. Mini-invasive Surg 2018;2:39 I http://dx.doi.org/10.20517/2574-1225.2018.23

DECLARATIONS
Authors’ contributions
Singh-Ranger G conceived and wrote the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
There are no conflict of interests.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol
Biomarkers Prev 2010;19:1893-907.
2. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut
1994;355:675-8.
3. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, et al. Prostanoids, ornithine decarboxylase, and polyamines in
primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;1262:425-31.
4. Singh Ranger G. Current Concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res 2014;34:6277-82.
5. Herschman HR. Prostaglandin synthase-2. Biochim Biophys Acta 1996;1299:125-40.
6. Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol
Morphol 2004;12:71-4.
7. Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.
Anticancer Res 2004;24:2349-51.
8. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, et al. Long-term use of aspirin and nonsteroidal anti-
inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23.
9. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
10. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, et al. Aspirin use and the risk for colorectal cancer and adenoma in
male health professionals. Ann Intern Med 1994;121:241-6.
11. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized
trial. J Natl Cancer Inst 1993;85:1220-4.
12. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s
Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
13. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational
follow-up of a randomized trial. Ann Intern Med 2013;159:77-85.
14. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, et al. Long-term effect of aspirin on colorectal cancer incidence and
mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
15. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med
2003;348:891-9.
16. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general
population. Ann Oncol 2015;26:47-57.
17. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, et al. Long-term use of nonsteroidal antiinflammatory drugs and
the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 2000;61:129-34.
18. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side